The Beijing Longitudinal Disability Survey in Community Elderly
Condition(s) studied
Study summary
The goal of this observational study is to establish the prospective cohort of the Beijing Longitudinal Disability Survey in Community Elderly (BLINDSCE) to explore the high-risk factors and preventive interventions for disability and cognitive impairment among community-dwelling adults aged 65 years and over. The main question it aims to answer is:
* What are the high-risk factors able to predict the incidence and advance of disability and cognitive impairment in community-dwelling adults aged 65 years and over?
* What are the categories of function and cognitive performance trajectory in community-dwelling adults aged 65 years and over?
Eligibility
Primary outcome measure(s)
- Disability from the individual's perspective — An average of 1 to 2 years
Disability is assessed using the 12-item World Health Organization's Disability Assessment Schedule 2.0 (WHODAS 2.0). The WHODAS 2.0 is a patient-reported disability measure, comprising six life domains involving cognition, mobility, self-care, interpersonal relationships, life activities, and participation. The total score of 12-item WHODAS 2.0 categorizes disability from no disability (score 0) to complete disability (score 48). - Disability from the medical's perspective — An average of 1 to 2 years
Disability is assessed using the basic activities of daily living (BADL) scale, the Katz Index scale. The minimum value is 0 , and the maximum value is 6. The higher the score, the better the outcome. - Disability from the medical's perspective — An average of 1 to 2 years
Disability is assessed using the instrumental activities of daily living (IADL) scale, the Lawton and Brody IADL scale. The minimum value is 0, and the maximum value is 8. The higher the score, the better the outcome.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Xuanwu Hospital, Capital Medical University | Beijing | China | Recruiting |
More Xuanwu Hospital, Beijing trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06863727 on ClinicalTrials.gov ↗ ← All trials in China